Rhenman & Partners Asset Management AB
Latest statistics and disclosures from Rhenman & Partners Asset Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BSX, LLY, ABBV, DHR, ALHC, and represent 18.39% of Rhenman & Partners Asset Management AB's stock portfolio.
- Added to shares of these 10 stocks: ABBV (+$14M), BSX (+$14M), UNH (+$11M), AXSM (+$10M), TMO (+$9.2M), DOCS (+$8.4M), IONS (+$8.4M), MDGL (+$8.4M), CYTK (+$8.3M), EW (+$7.8M).
- Started 13 new stock positions in VERA, OCUL, MLYS, ATEC, IRTC, UTHR, STVN, ADPT, GH, RYTM. STOK, MDGL, BTSG.
- Reduced shares in these 10 stocks: THC (-$16M), DXCM (-$14M), , VRNA (-$10M), GILD (-$9.8M), ALNY (-$8.8M), ELV (-$7.2M), OSCR (-$6.7M), , INSM (-$6.3M).
- Sold out of its positions in ASTH, DXCM, HCA, INMB, MOH, OSCR, RGEN, SYK, SMMT, VRNA. ALC.
- Rhenman & Partners Asset Management AB was a net buyer of stock by $82M.
- Rhenman & Partners Asset Management AB has $904M in assets under management (AUM), dropping by 14.24%.
- Central Index Key (CIK): 0001599882
Tip: Access up to 7 years of quarterly data
Positions held by Rhenman & Partners Asset Management AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB holds 92 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation (BSX) | 4.7 | $43M | +47% | 438k | 97.63 |
|
| Eli Lilly & Co. (LLY) | 4.5 | $41M | -7% | 53k | 763.00 |
|
| Abbvie (ABBV) | 3.3 | $30M | +87% | 130k | 231.54 |
|
| Danaher Corporation (DHR) | 2.9 | $27M | +10% | 135k | 198.26 |
|
| Alignment Healthcare (ALHC) | 2.9 | $26M | +14% | 1.5M | 17.45 |
|
| Intuitive Surgical Com New (ISRG) | 2.4 | $22M | +9% | 49k | 447.23 |
|
| UnitedHealth (UNH) | 2.4 | $22M | +105% | 63k | 345.30 |
|
| Axsome Therapeutics (AXSM) | 2.3 | $21M | +90% | 173k | 121.45 |
|
| CVS Caremark Corporation (CVS) | 2.3 | $21M | -6% | 277k | 75.39 |
|
| McKesson Corporation (MCK) | 2.3 | $21M | -4% | 27k | 772.54 |
|
| Regeneron Pharmaceuticals (REGN) | 2.2 | $20M | +30% | 36k | 562.27 |
|
| Ionis Pharmaceuticals (IONS) | 2.2 | $20M | +70% | 310k | 65.42 |
|
| Medtronic SHS (MDT) | 2.2 | $20M | +14% | 205k | 95.24 |
|
| AmerisourceBergen (COR) | 2.2 | $20M | +26% | 62k | 312.53 |
|
| EXACT Sciences Corporation (EXAS) | 2.1 | $19M | 348k | 54.71 |
|
|
| Insmed Com Par $.01 (INSM) | 2.1 | $19M | -24% | 132k | 144.01 |
|
| Glaukos (GKOS) | 2.1 | $19M | -2% | 230k | 81.55 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.0 | $18M | -23% | 47k | 391.64 |
|
| Insulet Corporation (PODD) | 2.0 | $18M | +26% | 58k | 308.73 |
|
| Cooper Cos (COO) | 1.8 | $16M | +39% | 237k | 68.56 |
|
| Neurocrine Biosciences (NBIX) | 1.8 | $16M | -23% | 115k | 140.38 |
|
| Encompass Health Corp (EHC) | 1.7 | $15M | -12% | 119k | 127.02 |
|
| Cardinal Health (CAH) | 1.6 | $15M | +70% | 94k | 156.96 |
|
| Thermo Fisher Scientific (TMO) | 1.6 | $15M | +169% | 30k | 485.02 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.6 | $15M | -37% | 32k | 456.00 |
|
| Cytokinetics Com New (CYTK) | 1.6 | $14M | +144% | 255k | 54.96 |
|
| Procept Biorobotics Corp (PRCT) | 1.5 | $14M | +105% | 390k | 35.69 |
|
| Cigna Corp (CI) | 1.5 | $13M | +45% | 47k | 288.25 |
|
| Abbott Laboratories (ABT) | 1.5 | $13M | +68% | 99k | 133.94 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 1.4 | $13M | -12% | 95k | 131.80 |
|
| Edwards Lifesciences (EW) | 1.3 | $12M | +181% | 155k | 77.77 |
|
| Tenet Healthcare Corp Com New (THC) | 1.3 | $12M | -57% | 58k | 203.04 |
|
| Akero Therapeutics (AKRO) | 1.2 | $11M | +16% | 231k | 47.48 |
|
| Align Technology (ALGN) | 1.2 | $10M | +24% | 83k | 125.22 |
|
| BioMarin Pharmaceutical (BMRN) | 1.1 | $10M | +24% | 187k | 54.16 |
|
| Doximity Cl A (DOCS) | 1.1 | $9.9M | +547% | 136k | 73.15 |
|
| Royalty Pharma Shs Class A (RPRX) | 1.0 | $9.1M | -24% | 259k | 35.28 |
|
| Gilead Sciences (GILD) | 1.0 | $8.9M | -52% | 80k | 111.00 |
|
| Syndax Pharmaceuticals (SNDX) | 1.0 | $8.8M | 574k | 15.38 |
|
|
| Madrigal Pharmaceuticals (MDGL) | 0.9 | $8.4M | NEW | 18k | 458.66 |
|
| Biogen Idec (BIIB) | 0.9 | $7.7M | +358% | 55k | 140.08 |
|
| Dynavax Technologies Corp Com New (DVAX) | 0.8 | $7.7M | +36% | 772k | 9.93 |
|
| Adaptive Biotechnologies Cor (ADPT) | 0.8 | $7.4M | NEW | 495k | 14.96 |
|
| Anthem (ELV) | 0.8 | $7.3M | -49% | 23k | 323.12 |
|
| Dianthus Therapeutics (DNTH) | 0.8 | $6.8M | +37% | 174k | 39.35 |
|
| Mineralys Therapeutics (MLYS) | 0.7 | $6.3M | NEW | 165k | 37.92 |
|
| Centene Corporation (CNC) | 0.7 | $6.1M | +70% | 170k | 35.68 |
|
| Stoke Therapeutics (STOK) | 0.7 | $5.9M | NEW | 250k | 23.50 |
|
| Viking Therapeutics (VKTX) | 0.6 | $5.7M | +154% | 216k | 26.28 |
|
| Anteris Technologies Global (AVR) | 0.6 | $5.6M | 1.3M | 4.50 |
|
|
| Arcellx Common Stock (ACLX) | 0.6 | $5.4M | -2% | 65k | 82.10 |
|
| Apellis Pharmaceuticals (APLS) | 0.6 | $5.3M | +149% | 232k | 22.63 |
|
| Penumbra (PEN) | 0.6 | $5.2M | -4% | 21k | 253.32 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.6 | $5.0M | +33% | 180k | 28.00 |
|
| Merus N V (MRUS) | 0.6 | $5.0M | -53% | 54k | 94.15 |
|
| Bruker Corporation (BRKR) | 0.6 | $5.0M | +25% | 154k | 32.49 |
|
| Natera (NTRA) | 0.6 | $5.0M | -46% | 31k | 160.97 |
|
| Privia Health Group (PRVA) | 0.5 | $4.8M | +112% | 194k | 24.90 |
|
| Nuvalent Inc-a (NUVL) | 0.5 | $4.5M | 53k | 86.48 |
|
|
| Inspire Med Sys (INSP) | 0.5 | $4.5M | +100% | 61k | 74.20 |
|
| Kura Oncology (KURA) | 0.5 | $4.3M | +96% | 490k | 8.85 |
|
| Mirum Pharmaceuticals (MIRM) | 0.5 | $4.1M | -14% | 56k | 73.31 |
|
| RadNet (RDNT) | 0.4 | $3.8M | +8% | 50k | 76.21 |
|
| Vera Therapeutics Cl A (VERA) | 0.4 | $3.8M | NEW | 130k | 29.06 |
|
| Iqvia Holdings (IQV) | 0.4 | $3.7M | +50% | 20k | 189.94 |
|
| Vericel (VCEL) | 0.4 | $3.7M | +101% | 117k | 31.47 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.4 | $3.6M | +28% | 119k | 30.08 |
|
| Biontech Se Sponsored Ads (BNTX) | 0.4 | $3.5M | 36k | 98.62 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 0.4 | $3.5M | NEW | 35k | 100.99 |
|
| Tg Therapeutics (TGTX) | 0.4 | $3.4M | -19% | 93k | 36.12 |
|
| United Therapeutics Corporation (UTHR) | 0.4 | $3.4M | NEW | 8.0k | 419.21 |
|
| Xenon Pharmaceuticals (XENE) | 0.4 | $3.3M | +131% | 81k | 40.15 |
|
| Nurix Therapeutics (NRIX) | 0.4 | $3.2M | +87% | 348k | 9.24 |
|
| Guardant Health (GH) | 0.3 | $3.1M | NEW | 50k | 62.48 |
|
| Alkermes SHS (ALKS) | 0.3 | $2.8M | +141% | 94k | 30.00 |
|
| Livanova SHS (LIVN) | 0.3 | $2.8M | 53k | 52.38 |
|
|
| Annexon (ANNX) | 0.3 | $2.5M | +78% | 823k | 3.05 |
|
| Universal Hlth Svcs CL B (UHS) | 0.3 | $2.5M | -53% | 12k | 204.44 |
|
| Janux Therapeutics (JANX) | 0.3 | $2.4M | +81% | 100k | 24.44 |
|
| Relay Therapeutics (RLAY) | 0.3 | $2.4M | 460k | 5.22 |
|
|
| Iovance Biotherapeutics (IOVA) | 0.3 | $2.4M | +69% | 1.1M | 2.17 |
|
| Ocular Therapeutix (OCUL) | 0.3 | $2.4M | NEW | 202k | 11.69 |
|
| Krystal Biotech (KRYS) | 0.2 | $2.1M | -7% | 12k | 176.53 |
|
| Xencor (XNCR) | 0.2 | $1.9M | 166k | 11.73 |
|
|
| Brightspring Health Svcs (BTSG) | 0.2 | $1.8M | NEW | 60k | 29.56 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.2 | $1.5M | +360% | 207k | 7.17 |
|
| Denali Therapeutics (DNLI) | 0.2 | $1.5M | 100k | 14.52 |
|
|
| Stevanato Group S P A Ord Srs (STVN) | 0.1 | $1.3M | NEW | 51k | 25.75 |
|
| Irhythm Technologies (IRTC) | 0.1 | $1.2M | NEW | 7.0k | 171.99 |
|
| Immunocore Hldgs Ads (IMCR) | 0.1 | $1.0M | 28k | 36.33 |
|
|
| Bio-techne Corporation (TECH) | 0.1 | $835k | 15k | 55.63 |
|
|
| Alphatec Hldgs Com New (ATEC) | 0.0 | $262k | NEW | 18k | 14.54 |
|
Past Filings by Rhenman & Partners Asset Management AB
SEC 13F filings are viewable for Rhenman & Partners Asset Management AB going back to 2013
- Rhenman & Partners Asset Management AB 2025 Q3 filed Nov. 13, 2025
- Rhenman & Partners Asset Management AB 2025 Q2 filed Aug. 13, 2025
- Rhenman & Partners Asset Management AB 2025 Q1 filed May 14, 2025
- Rhenman & Partners Asset Management AB 2024 Q4 filed Feb. 13, 2025
- Rhenman & Partners Asset Management AB 2024 Q3 filed Nov. 13, 2024
- Rhenman & Partners Asset Management AB 2024 Q2 filed Aug. 13, 2024
- Rhenman & Partners Asset Management AB 2024 Q1 filed May 14, 2024
- Rhenman & Partners Asset Management AB 2023 Q3 restated filed Nov. 13, 2023
- Rhenman & Partners Asset Management AB 2023 Q3 filed Nov. 9, 2023
- Rhenman & Partners Asset Management AB 2023 Q2 filed Aug. 11, 2023
- Rhenman & Partners Asset Management AB 2023 Q1 filed May 12, 2023
- Rhenman & Partners Asset Management AB 2022 Q4 filed Feb. 13, 2023
- Rhenman & Partners Asset Management AB 2022 Q3 filed Nov. 14, 2022
- Rhenman & Partners Asset Management AB 2022 Q2 filed Aug. 12, 2022
- Rhenman & Partners Asset Management AB 2022 Q1 filed May 13, 2022
- Rhenman & Partners Asset Management AB 2021 Q4 filed Feb. 11, 2022